PARSIPPANY, N.J., Sept. 29 /PRNewswire/ -- Ferring Pharmaceuticals
today announced a new, expanded cost-saving program for patients who are
considering fertility treatment, but find the costs a challenge. Ferring's
HEART (Helping Expand Access to Reproductive Therapy) Rx Initiative gives
women greater access to fertility medications by providing significant cost
savings on two frequently prescribed fertility treatments. The program now
includes both BRAVELLE(R) (urofollitropin for injection, purified) and
MENOPUR(R) (menotropins for injection, USP).
"In our ongoing effort to increase access to safe, effective fertility
treatments, we have expanded our long-time HEART Program, now called the
HEART Rx Initiative, to give qualified couples a greater chance to build
families," said Olivier Delannoy, Vice President, Infertility Business
Unit. "Cost should not be a barrier to parenthood."
With Ferring's expanded HEART Rx Initiative, cash-paying patients save
up to $2,100 on BRAVELLE and MENOPUR. The program helps reduce costs for
patients undergoing ovulation induction, donor or in vitro fertilization
cycles. Full program details are available at
How the Program Works
If you are a cash-paying patient and your doctor prescribes a fertility
treatment, ask the doctor if these products are right for you and if you
qualify for the HEART Rx Initiative.
-- To receive the savings, your doctor will give you a HEART Rx brochure
along with the prescription.
-- Take the prescription and brochure to a participating pharmacy. For a
list of participating pharmacies, visit www.ferringfertility.com/HEART.
-- Pay a $10 enrollment fee for the annual membership. The pharmacist will
give you a membership number.
-- Fill out the membership card. You will automatically receive the
cost-savings each time you fill the prescription.
For more information, speak to your doctor or call 1-888-FERRING
About BRAVELLE and MENOPUR
BRAVELLE and MENOPUR, like all gonadotropins, are potent substances
capable of causing mild to severe adverse reactions, including OHSS
(incidence of 6.0% and 3.8%, respectively), with or without pulmonary or
vascular complications, in women undergoing therapy for infertility. Like
other products for ovarian stimulation, treatment with BRAVELLE and/or
MENOPUR may result in multiple gestations. Only physicians thoroughly
familiar with infertility treatment, including the risk of multiple births
and adverse reactions, should prescribe these medications.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned,
international pharmaceutical company, manufactures and markets the largest
family of fertility treatments of any manufacturer in the U.S. The Company
markets MENOPUR, BRAVELLE, REPRONEX(R) (menotropins for injection, USP),
NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R)
(progesterone) Vaginal Insert 100 mg in the U.S. to infertility specialists
and their patients. Ferring also offers the Q-CAP(TM), the first and only
needle-free reconstitution device, for use with its fertility treatments.
Ferring's line of orthopaedic and urology products includes EUFLEXXA(R)
(1% sodium hyaluronate) hyaluronic acid for pain from osteoarthritis in the
knee and PROSED(R)/DS for the relief of discomfort of the lower urinary
tract. Other products include: ACTHREL(R) (corticorelin ovine triflutate
for injection) for the differential diagnosis of Cushing's syndrome; and
DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment
of diabetes insipidus and primary nocturnal enuresis.
The Ferring Group specializes in the research, development and
commercialization of compounds in general and pediatric endocrinology,
urology, gastroenterology, obstetrics/ gynecology and infertility. For more
information, call 888-337-7464 or visit www.ferringusa.com or
Please contact Andrea Preston for full prescribing information for
BRAVELLE and MENOPUR.
SOURCE Ferring Pharmaceuticals